Cue Biopharma
77 hedge funds and large institutions have $31M invested in Cue Biopharma in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 27 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
33% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 27
Holders
77
Holding in Top 10
–
Calls
$292K
Puts
$88K
Top Buyers
| 1 | +$1.89M | |
| 2 | +$369K | |
| 3 | +$353K | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$284K |
| 5 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$278K |
Top Sellers
| 1 | -$339K | |
| 2 | -$189K | |
| 3 | -$179K | |
| 4 |
AC
Annandale Capital
Dallas,
Texas
|
-$172K |
| 5 |
Jane Street
New York
|
-$144K |